News & Events
Alzheimer’s may increase DNA variants in brain neurons
Study finds that Alzheimer’s neurons accumulate more DNA variants than occur from aging alone. The pattern of the variants is linked to oxidative damage and problems with DNA repair processes.
Hydroxychloroquine lowers dementia risk in humans, improves molecular signs of Alzheimer’s in mouse and cell models
Hydroxychloroquine is linked to lower dementia risk in older individuals and can reduce molecular signs of Alzheimer’s in mouse and cell models, according to an NIA study.
Links found between viruses and neurodegenerative diseases
A research team led by NIH’s Center for Alzheimer’s and Related Dementias found 45 associations between viruses and neurodegenerative diseases with the strongest link between viral encephalitis and Alzheimer’s.
Study of green tea and other molecules uncovers new therapeutic strategy for Alzheimer’s
Researchers have observed how a molecule found in green tea dismantles tau tangles found in Alzheimer’s disease, leading to discovery of additional molecules that can untangle tau and are potential Alzheimer’s treatments.
Estimates of amyloid onset may predict Alzheimer’s progression
Determining how long beta-amyloid plaques have been building up in a person’s brain may help predict the course of their Alzheimer’s disease.
Could a viral illness increase chances of developing Alzheimer’s or other neurodegenerative disease?
Some viral illnesses may increase a person’s chances of later developing Alzheimer’s disease or another neurodegenerative disorder. Though a causal link cannot be confirmed, an NIH study found significant associations.
Blood test for early Alzheimer’s detection
NIA-funded researchers develop blood test for early Alzheimer’s detection.
Take care of your senses: The science behind sensory loss and dementia risk
Read about NIA-funded research that is uncovering new insights on how hearing, vision, and smell may play a role in overall cognitive health.
FDA grants accelerated approval for Alzheimer’s disease treatment
The U.S. Food and Drug Administration approves lecanemab via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.
Education and gender inequality may explain why India’s women have worse late-life cognition
Education and other disparities may explain gender differences in late-life cognition, according to an NIA-funded study of data from nearly 50,000 older adults in India.